The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
MAXALT MIGRAINE RELIEF rizatriptan 5 mg (as benzoate) wafer blister pack, ORGANON PHARMA PTY LTD, CON-1106
Product name
MAXALT MIGRAINE RELIEF rizatriptan 5 mg (as benzoate) wafer blister pack
Sponsor name
ORGANON PHARMA PTY LTD
Batches
5109201
Consent start
Consent no.
CON-1106
Duration
The consent is effective from 18 May 2023 until 25 April 2024.
Standard
paragraphs 8(1)(a), 9(1)(a) and 10(8)(a)(vi) of Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines
Non-compliance with standard
The product does not comply because the medicine name on the foil blister and
the sachet labels is slightly different to the approved name included in the
Australian Register of Therapeutic Goods and the foil blister label displays the
name of the active ingredient as rizatriptan instead of rizatriptan (as
benzoate).
Therapeutic product type
Over-the-counter medicines